 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment change, Combination therapy, Monotherapy, Metastases: SKB264-II-04: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 20, 2024
P2, N=498, Recruiting, Sponsor: Klus Pharma Inc.
N=278 --> 498
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Aug 23, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=278 --> 498 Not yet recruiting --> Recruiting
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Monotherapy, Metastases: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov) - Jul 30, 2024
P3, N=686, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov) - Jul 29, 2024
P1/2, N=90, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Trofuse-009: Phase 3 Study of Sac-TMT vs Platinum-Doublet Chemotherapy for Previously Treated EGFR-Mutated Advanced NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1575;
P3
Secondary endpoints include objective response rate, duration of response, patient-reported outcomes, and safety. Enrollment in this study will begin in May 2024.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC with EGFR/Other Genomic Alterations (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1574;
P3
Health-related quality oflife PROs will be measured using the EORTC QLQ-C30 and EORTC QLQ-LC13. Enrollmentstarted in November 2023 and is currently ongoing.
- Keytruda (pembrolizumab) / Merck (MSD)
Trofuse-019: A Phase 3 Study of Adjuvant Pembrolizumab with or without Sac-TMTfor Resectable Stage II-IIIB (N2) NSCLC (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1370;
P3
Secondary endpoints include OS, distant metastasis-free survival (time from randomization to first documented distant metastasis by investigator review or death), disease-free survival by investigator review, lung cancer-specific survival (time from randomization to death due to lung cancer), safety, and patient-reported outcomes. Enrollment into this study will begin in April 2024.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Phase 3 Trofuse-007 Study: Sacituzumab Tirumotecan Plus Pembrolizumab vs Pembrolizumab Alone for NSCLC with PD-L1 TPS ?50% (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1218;
AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Enrollment began in December 2023 and is currently ongoing.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
MK-2870-015: A phase 3 study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician's choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3151;
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT) Monotherapy vs Treatment of Physician's Choice Chemotherapy in Patients With Endometrial Cancer Who Have Received Prior Chemotherapy and Immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005 (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2551;
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone and With Pembrolizumab vs Treatment of Physician's Choice Chemotherapy (TPC) in Patients With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (mBC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2348;
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov) - Jul 9, 2024
P1/2, N=98, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Enrollment began in December 2023 and is currently ongoing. Not yet recruiting --> Recruiting
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Combination therapy, Metastases: A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) (clinicaltrials.gov) - Jul 3, 2024
P1/2, N=98, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Phase classification, Combination therapy, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - Jun 26, 2024
P1/2, N=130, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Metastases: SKB264-?-11: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Jun 26, 2024
P3, N=524, Recruiting, Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2 Not yet recruiting --> Recruiting
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: U1111-1301-2790: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov) - Jun 24, 2024
P3, N=851, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Metastases: KEYMAKER-06C: Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) (clinicaltrials.gov) - Jun 23, 2024
P1/2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- || sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Trial completion date, Combination therapy, Monotherapy, Metastases: SKB264-II-04: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 21, 2024
P2, N=278, Recruiting, Sponsor: Klus Pharma Inc.
Not yet recruiting --> Recruiting Trial completion date: Apr 2026 --> Aug 2026
- ||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date, Metastases: KL264-01: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (clinicaltrials.gov) - Jun 21, 2024
P1/2, N=1300, Recruiting, Sponsor: Klus Pharma Inc.
Trial completion date: Apr 2026 --> Aug 2026 N=430 --> 1300 | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Aug 2025
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Surgery: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (clinicaltrials.gov) - Jun 19, 2024
P3, N=1530, Recruiting, Sponsor: Merck Sharp & Dohme LLC
N=430 --> 1300 | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Aug 2025 Not yet recruiting --> Recruiting
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Monotherapy, Metastases: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov) - Jun 14, 2024
P3, N=686, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: TroFuse-009: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov) - Jun 13, 2024
P3, N=520, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P1/2 trial, Combination therapy, Metastases: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) (clinicaltrials.gov) - Jun 5, 2024
P1/2, N=90, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P1/2 trial, New P2 trial, Combination therapy, Monotherapy: A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov) - May 24, 2024
P2, N=130, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy, Metastases: U1111-1301-2790: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov) - May 20, 2024
P3, N=851, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Metastases: TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov) - May 13, 2024
P3, N=450, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy, Surgery: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (clinicaltrials.gov) - May 1, 2024
P3, N=1530, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2909;
P3
trial, SKB264 was compared with physician's choice of chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in pts with locally recurrent or metastatic TNBC who had received two or more prior therapies including at least one for metastatic setting... Sacituzumab tirumotecan monotherapy demonstrated statistically significant and clinically meaningful PFS and OS benefit over chemotherapy, with a manageable safety profile in pts with heavily pretreated advanced TNBC and limited treatment options.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), tagitanlimab (HBM9167) / Harbour BioMed
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. (Arie Crown Theater) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1381;
P2, P3
A Phase 3 study of SKB264 Q2W plus pembrolizumab vs pembrolizumab in 1L metastatic NSCLC with PD-L1 TPS ? 50% (NCT06170788) is ongoing.
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Surgery: TroFuse-019: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov) - Apr 17, 2024
P3, N=780, Recruiting, Sponsor: Merck Sharp & Dohme LLC
50% (NCT06170788) is ongoing. Not yet recruiting --> Recruiting
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Metastases: TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov) - Apr 10, 2024
P3, N=450, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Metastases: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov) - Apr 4, 2024
P3, N=1200, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Surgery: TroFuse-019: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (clinicaltrials.gov) - Mar 15, 2024
P3, N=780, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy, Metastases: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (clinicaltrials.gov) - Mar 15, 2024
P3, N=1200, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Combination therapy, Metastases: TroFuse-009: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov) - Mar 12, 2024
P3, N=520, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study (Hall GH - Ground Level - Convention Center) - Mar 5, 2024 - Abstract #AACR2024AACR_8743;
Not yet recruiting --> Recruiting Abstract is embargoed at this time.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ?50% (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7914;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with EGFR mutations or other genomic alterations (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_7913;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study (Section 48) - Mar 5, 2024 - Abstract #AACR2024AACR_7881;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P3 trial, Metastases: SKB264-?-11: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Feb 27, 2024
P3, N=524, Not yet recruiting, Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study () - Jan 22, 2024 - Abstract #YIR2024YIR_121;
P1/2, P2,
Higher response rate was seen in mTNBC pts with high TROP2 expression. A Phase 3 study of SKB264 vs.
- || Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov) - Jan 9, 2024
P1/2, N=200, Recruiting, Sponsor: Merck Sharp & Dohme LLC
A Phase 3 study of SKB264 vs. Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Feb 2025 --> Nov 2026
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy, Monotherapy, Tumor proportion score, Metastases: Trofuse-007: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ? 50% (MK-2870-007) (clinicaltrials.gov) - Jan 4, 2024
P3, N=614, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Feb 2025 --> Nov 2026 Not yet recruiting --> Recruiting
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Monotherapy: ENGOT-en23: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (clinicaltrials.gov) - Dec 14, 2023
P3, N=710, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial, Combination therapy, Monotherapy, Tumor proportion score, Metastases: Trofuse-007: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ? 50% (MK-2870-007) (clinicaltrials.gov) - Dec 14, 2023
P3, N=614, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
- | sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. (clinicaltrials.gov) - Dec 14, 2023
P2, N=110, Recruiting, Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
- || sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Phase classification, Monotherapy: ENGOT-en23: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (clinicaltrials.gov) - Dec 13, 2023
P3, N=710, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024 Phase classification: P2/3 --> P3
- |||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
Enrollment open, Metastases: TroFuse-004: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) (clinicaltrials.gov) - Nov 18, 2023
P3, N=556, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P2/3 --> P3 Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Metastases: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=200, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting N=300 --> 200
- |||||||||| sacituzumab tirumotecan (MK-2870) / Merck (MSD)
New P2/3 trial, New P3 trial, Monotherapy: ENGOT-en23: Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (clinicaltrials.gov) - Nov 15, 2023
P2/3, N=710, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC